In adult heart, selective PKC activation limits ischemia/reperfusion (I/R) damage and mimics the protection associated with ischemic preconditioning. We sought to determine whether local delivery of an PKC -activator peptide () RACK) is sufficient to produce a similarly protected phenotype in aged hearts. Langendorff-perfused hearts isolated from adult (5 mo; n=9) and aged (24 mo; n=9) male Fisher 344 rats were perfused with either ) RACK conjugated to Tat (500 nM) or Tat-only (500 nM) for 10 min prior to global 31 min ischemia. Western blotting was used to measure mitochondrial targeting of PKC , PKC6, p-GSK-39 (ser9) and GSK-39 in hearts snap frozen during I. Recovery of LV developed pressure was significantly improved by ) RACK (p<0.01) and infarct size reduced in 24 mo vs age-matched controls (60% vs 34%; p<0.01). Mitochondrial PKC levels were 30% greater during I with ) RACK in aged vs controls (p<0.01). Interestingly, mitochondrial GSK-39 levels were 3-fold greater in aged vs adult during I, and ) RACK prevented this increase (p<0.01). Mitochondrial p-GSK-3 9 levels were also greater in aged following ) RACK (p<0.01), and subsequent inhibition of GSK-39 with SB 216763 (3 uM) prior to I/R elicited protection similar to that observed for ) RACK (n=3/group). Mitochondrial proteomic analysis further identified group differences in the F 1 -ATPase-9 subunit, and coimmunoprecipitation studies revealed a novel interaction with PKC .
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INTRODUCTION
Human hearts as well as those from experimental animals demonstrate a markedly reduced tolerance to ischemic stress during normal aging (1, 23, 33, 34) . This age-associated decrease in ischemic tolerance plays a central role in the increased incidence and mortality rates from myocardial infarction observed with advancing age (44). Exacerbating the problem is the observation that the aged heart is refractory to some, but not all, cardioprotective interventions.
For example, chronic exercise training appears to improve ischemic tolerance in the aged rat heart (12), but ischemic preconditioning (IPC), where brief periods of ischemia protects the myocardium from subsequent ischemic insult (39) , is essentially absent in the aged (for review see (28) . Accordingly, there is great interest in determining the molecular basis for the reduced ischemic tolerance in the aged heart, and also for identifying clinically applicable cardioprotective strategies that are efficacious with senescence.
Multiple lines of evidence suggest that activation of PKC -dependent signaling pathways play a pivotal role in cardioprotection and resistance to ischemic insult. Translocation of PKC to the mitochondria is thought to induce opening of mitochondrial K ATP channels, as well as inhibit the mitochondrial transition pore (MPT) (5, 30, 37) , thereby protecting against Ca 2+ overload injury and apoptosis. In this regard, our recent observation of reduced PKC levels in the aged heart at baseline and following ischemia may contribute to the mechanism of ischemic intolerance and reduced efficacy of IPC with advancing age (33). Additional evidence supporting the importance of PKC in cardioprotection are data from Inagaki and colleagues (25, 26) who demonstrated that acute activation of PKC conjugated to the cell-permeating carrier peptide Tat immediately prior to global ischemia is sufficient to reduce infarct size in young adult rats, suggesting that IPC can be mimicked through pharmacological manipulation of PKC (25) .
However, the efficacy of acute PKC activation has yet to be tested in the aged population. Given the diminished effectiveness of IPC in the aged heart, combined with our observation of age-related reductions in cardiac PKC levels, the extent to which specific PKC activation can confer cardioprotective benefit to the aged heart may be limited.
The major purpose of the current investigation was to therefore test the hypothesis that acute pharmacological activation of PKC prior to ischemia would be sufficient to harness cardioprotective signaling reserves in the aged rat heart. Because the mitochondria are critically involved in transducing the coordinated cellular response to ischemia (29, 38), we utilized a proteomic approach within the mitochondrial compartment to identify potential targets of PKCmediated cardioprotection affected by senescence. For instance, glycogen synthase kinase-3 (GSK-3 ) has been identified as an important down-stream effector of PKC -mediated protection in cardiac mitochondria through inhibition of the MPT (5, 30, 37); and recent evidence from our laboratory suggest that age-related increases in active GSK-39 during reperfusion are highly correlated with I/R injury (23, 33) . Here, we present evidence for the first time that acute augmentation of mitochondrial PKC levels during ischemia as a result of local delivery of a PKC activating peptide is highly effective in reducing infarct size in the aged heart. Our data further suggest a novel interaction of the mitochondrial F 1 -ATPase-9 subunit with PKC , as well as adaptive responses in the activation of mitochondrial GSK-39 during ischemia.
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Protocol of the Isolated Heart Studies.
Following equilibration, ) RACK conjugated to Tat (500 nM) or Tat vehicle peptide alone (500 nM) was administered in the perfusate 10 min prior to global ischemia (see Figure 1 ).
Hearts were then subjected to 31 min global, ischemia as described previously (23, 33) . Pacing was re-initiated 1 min after restoring flow and hearts were reperfused for 30 min. Administration of the PKC activator prior to global ischemia is based on previous studies whereby PKCmodulating peptides were shown previously to be cardioprotective using this exposure duration and concentration (7, 26) , readily distributing throughout cardiac tissue. In a separate series of studies, adult and aged hearts (n=3/group) were perfused with the GSK-39 inhibitor SB 216763 (3 uM; Tocris) 10 min prior to ischemia in an identical fashion to the protocol associated with ) RACK administration. Creatine kinase release (Stan Bio) was assessed in coronary effluents to assure significant injury was induced by the experimental protocol. Following reperfusion left ventricles (LV) were isolated, weighed, halved and frozen in liquid N 2 . All LV sections were stored at -80OC until tissue preparation.
Triphenyltetrazolium Chloride Staining
To assess infarct size, a subset of hearts (n=4/group) underwent 31 min normothermic ischemia followed by ~2h reperfusion and the area of infarction was assessed exactly as described (33). Briefly, following reperfusion, LV were isolated and frozen at -20°C for 30 min.
Left ventricles were sliced transversely and stained with 1% triphenyltetrazolium chloride (TTC) in phosphate buffer for 30 minutes at 37°C. Digital images of infarcted LV were analyzed using NIH ImageJ software.
Tissue Sample Preparation
Cytosolic and mitochondrial samples were prepared exactly as described previously in our laboratory (22, 23, 33) . Briefly, frozen LV samples were homogenized by glass-glass grinder in 10 vol lysis buffer and subjected to serial centrifugations of 10,000 x g and 100,000 x g, respectively. The 10,000 x g pellet (mitochondrial fraction) was resuspended and subjected to a 21,000 x g centrifugation for 10 min. The resultant supernatant was defined as the mitochondrial fraction. The 100,000 x g supernatant was defined as the cytosolic fraction. All protein concentrations were determined by the method of Bradford (11). Citrate synthase activity was also assessed in mitochondrial homogenates at baseline and during ischemia using a modification of the method of Srere (45) and used as a marker of mitochondrial yield and viability .
Western Blotting
Western blotting was performed according to well established procedures in our laboratory (31, 32). Briefly, equal amounts of cytosolic (cytochrome C) or mitochondrial (PKC, p-GSK39 (Ser 9 ), GSK39) protein were electrophoresed on SDS-polyacrylamide gels (PAGE) and transferred to PVDF membranes. Membranes were blocked and incubated with rabbit polyclonal antibodies against PKC (1:1200) or PKC (1:1500) for 3h at room temperature or p-GSK39(Ser 9 ), GSK39, and cytochrome C (1:1000) overnight at 4OC. Immunoreactive bands were detected using HRP-linked anti-rabbit IgG (1:15000) and enhanced chemiluminescence (ECL; Amersham). Densitometry was performed using Scion Image (NIH).
To control for total GSK39 protein levels, membranes were initially incubated with p-GSK39 antibodies then stripped by 30 min incubation (70OC) in buffer containing: 62.5 mM
Tris-HCl pH 6.80, 7% 2-mercaptoethanol, 2% SDS. Membranes were then probed for total levels of GSK39 as described above and expressed as a ratio. To control for minor differences in protein loading, membranes were stained with Sypro Ruby (PKC6, PKC ) or Ponceau S (p-GSK39, GSK39) and densitometry values were adjusted as described previously (43). All group western data are presented relative to pre-ischemic values in adult animals.
2-DE Gel Electrophoreses and Mass Spectrometry.
Mitochondrial homogenates were isolated from LV of untreated adult and aged rats as described above and subjected to two-dimensional electrophoresis (2-DE). Proteins (~200 µg/sample) were separated in the first dimension by isoelectric point on IPG strips (BioRad) with a linear pH gradient from 3-10 (9). SDS-PAGE was performed on IPG strips using 12% separating gels, which were later stained with Sypro Ruby and imaged (Flour-S, BioRad).
Protein images were analyzed using PD Quest software (Bio-Rad version 7.2) and matched sets (n=3 hearts/group) were generated.
Mass spectrometry (MS) Analysis. Protein spots were excised and subjected to trypsin Identification of peptides from the MS/MS spectra was done by the Mascot algorithm.
Assessment of PKC -F 1 -ATPase subunit Associations. Mitochondrial samples (400 µg) from adult and aged hearts treated with ) RACK or vehicle were diluted to 4 ml with RIPA buffer (10 mM Tris-HCl, pH 7.2; 150 mM NaCl; 1% deoxycholate; 1% Triton X-100; 0.1% SDS) and incubated with 5 µl of rabbit polyclonal antibodies against PKC for 2hr (4OC).
Following 30 min incubation with protein A sepharose, the beads were washed three times according to previously published procedures from our laboratory (22) . Samples were electrophoresed on 7.5% polyacrylamide gels and resulting membranes probed with F 1 -ATPase subunit (1:3000).
Statistical Analyses
All data are presented as mean ± standard error and analyzed using the Statistical Analysis System (SAS). Baseline data and infarct size were compared with a two-way ANOVA. 
RESULTS
Rat
Heart Characteristics. Table 1 shows morphological and baseline cardiac functional data for adult (n=9/group) and aged (n=9/group) rats with or without ) RACK. LV and body weights were significantly greater in aged animals compared with adults (p<0.01). As we have reported previously (23, 33) , aging also resulted in a small but significant decrease in -dP/dt (p<0.05). No significant group differences for any baseline variables of interest were observed between adult and aged animals treated with ) RACK vs Tat-only.
Acute PKC activation improves post-ischemic recovery and reduces infarct size in aged
rat heart. Recovery of LVDP following ischemia is presented in Figure 2 . A significant reduction in recovery LVDP was observed in aged vs adult (closed triangles vs closed circles;
p<0.05). In contrast, hearts perfused with ) RACK prior to ischemia showed improved recovery when compared to hearts perfused with Tat-only (closed vs open symbols; p<0.01). The efficacy of ) RACK was particularly apparent during the early period of reperfusion such that at min 5, recovery LVDP was 50% greater in aged and adult hearts, respectively (p<0.01). Parallel reductions in EDP were also observed with ) RACK (p<0.01; Figure 3 ).
In a subset of experiments, hearts (n=4-5/group) were subjected to TTC staining following 110 min of reperfusion to assess infarct size. As seen in Figure 4 , infarct size was significantly greater in aged vs adult hearts (p<0.01) as we have demonstrated previously (23, 33) . Importantly, acute PKC activation with ) RACK prior to ischemia was highly effective in reducing infarct size in the aged group from ~60% in age-matched controls to 34% (p<0.01). A similar pattern was observed for integrated creatine kinase release (not shown) and cytosolic cytochrome C levels ( Figure 5 ). Collectively, these data are consistent with a protective role for acute PKC activation in the aged male rat heart.
Acute PKC Activation alters Mitochondrial PKC Levels During Ischemia. Figure 6A shows that mitochondrial PKC levels are reduced during ischemia relative to baseline in aged but not adult male rats (40%; p<0.01), suggesting that the aged male heart is unable to maintain mitochondrial PKC levels to the same extent as adult rats during ischemia. However, ) RACK administration prior to ischemia was effective in preserving mitochondrial PKC levels ( Figure   6A ). Specifically, augmentation of cardiac mitochondrial PKC levels during ischemia was observed in both aged and adult rats following ) RACK vs age-matched controls perfused with Tat-only ( Figure 6A ; p<0.01). While a significant age-related increase was observed in mitochondrial PKC6 levels at baseline and during ischemia ( Figure 6B; ).
Mitochondrial Targets of PKC -Mediated Cardioprotection.
One downstream mechanism by which PKC may confer cardioprotection includes phosphorylation and inactivation of mitochondrial GSK-39 (29). Our previous studies (23, 33) indicated age-related increases in both basal p-GSK-39 and GSK-39, which were confirmed herein ( Figure 7A and 7B). During ischemia, we observed significantly greater mitochondrial p-GSK-39 levels in aged vs adult in Tat-only treated hearts ( Figure 7A ; p<0.05). Unexpectedly, we also observed an agedependent increase in active, mitochondrial GSK-39 of~three-fold ( Figure 7B ; p<0.01),
suggesting greater GSK-39 activation with aging. Importantly, mitochondrial p-GSK-3 levels were significantly increased in aged and adult following RACK, thereby increasing the p-GSK-3 /GSK-3 ratio. Prior exposure to ) RACK also prevented translocation of GSK-39 to the mitochondria in aged, presumably limiting mitochondrial GSK-39 activation (Panel 7B; p <0.01). Interestingly, perfusion of hearts with the GSK-39 specific inhibitor SB 216763 prior to ischemia resulted in improved recovery of LVDP in aged hearts similar to that observed for ) RACK (Figure 8 ). Taken together, our results support an important role for mitochondrial GSK-3 as a potential target to limit I/R damage with aging following acute PKC activation.
Mitochondrial homogenates isolated from LV of adult and aged, male rats were also subjected to 2-DE gel electrophoresis. Matched sets (n=3 hearts/group) were prepared and a representative 2-DE map of rat mitochondrial proteins was generated (not shown). Within the pH gradient studied, we detected n=306 to n=440 well-defined spots among groups. We observed n=10 spots differentially expressed in aged but not adult. One of the spots identified through mass spectrometry analysis was the mitochondrial F 1 -ATPase subunit, a key enzyme involved in ATP synthesis and energy metabolism. The molecular size and PI of this spot was consistent with the F 1 -ATPase subunit and based on at least 20 mass peak identifications.
Co-immunoprecipation studies further revealed a significant interaction of the F 1 -ATPase-subunit with PKC in mitochondrial homogenates ( Figure 9A ), suggesting that alterations in ischemia-dependent phosphorylation (via PKC ) of the F 1 9-subunit may contribute to age-dependent alterations in ischemic tolerance. Interestingly, aging was associated with a significant reduction in F 1 -ATPase interaction with PKC during ischemia (p<0.05). Further, while a significant effect of ) RACK was also observed on reducing F 1 -ATPase-subunit interactions with PKC in adult ( Figure 9B ), ) RACK was without effect in aged.
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DISCUSSION
Current experimental evidence suggest that hearts isolated from both aged humans and animals demonstrate reduced tolerance to superimposed ischemic stresses, contributing to the greater than 50% increased incidence of myocardial infarction in men over the age of 65 years when compared to their adult counterparts (44). Given known reductions in ischemic tolerance in the aged myocardium (1, 23, 33, 34) , the efficacy of pharmacological manipulation by IPC mimetics such as PKC activating peptides to trigger cardioprotection was uncertain. Key findings of the current investigation include the observation that acute activation of PKC augmented mitochondrial PKC during ischemia, abrogated mitochondrial GSK-39 levels, and reduced infarct size in the aged male rat heart. Proteomic analysis revealed a possible mechanistic role for the mitochondrial F 1 -ATPase-9 subunit in the genesis of aged-related reductions in ischemic intolerance, and a novel F 1 ATPase-PKC association. Taken together, our results suggest for the first time that acute manipulation of mitochondrial PKC is sufficient to improve ischemic tolerance in the aged male rat heart, the cellular basis of which is likely to involve reductions in necrotic and apoptotic cell death.
A major purpose of the current investigation was to determine the efficacy of acute PKC activation to limit I/R damage in the aged male rat heart. Recent studies have identified PKC as a key modulator of cardioprotection and a novel therapeutic target for infarct size reduction and improved ischemic tolerance in adult animals (15, 25, 26) , thereby mimicking the effects of IPC.
Here, we extend these results to the aged male heart and observed reversal of age-related reductions in recovery of LVDP in hearts treated with ) RACK when compared to controls.
Most dramatic differences were observed early during the reperfusion period, when initiation of apoptotic cell death signaling is likely to occur. Infarct size was also significantly reduced by ~50%, and attenuation of additional markers of cell death including creatine kinase and cytochrome C release were observed in aged hearts treated with ) RACK. Collectively, these data provide important evidence in support of the potential clinical application of acute PKC activation in the treatment of acute coronary syndrome in the aged male population.
While the mechanism(s) by which PKC limits infarct size are incompletely understood, particularly with regard to its role in IPC (39), localization of PKC to the mitochondria and phosphorylation of downstream targets is a critical step in engaging cell survival signaling (18, 41) . However, aging studies to date have focused on signaling during the reperfusion period, and it may be that events during ischemia could provide important clues to understanding the cellular basis of ischemic intolerance with aging. Previous findings from our laboratory suggest that mitochondrial PKC levels are indeed reduced in the aged rat heart during reperfusion following ischemia (22, 23, (31) (32) (33) . Here, we demonstrate that augmentation of mitochondrial PKC levels following ) RACK can mimic the protective effects of IPC in the aged myocardium. However given findings from several recent studies utilizing PKC modulatory peptides (13, 19, 26, 27) , it is unclear whether the PKC -activating effect mediated by ) RACK reflects altered translocation of PKC to the mitochondria or activation of constitutively expressed PKC and hence greater association with its RACK. A limitation of the current study is that PKC levels were examined at only one time point during ischemia and effects of ) RACK treatment on the temporal activation of PKC during ischemia remains unknown. Alternatively, differences in PKC proteolytic activity or sensitivity to lipid activators may be altered by ) RACK to enhance the activating effect of PKC under conditions of I/R. Future studies targeting the mechanism by which ) RACK alters PKC activation, particularly in the aged heart are therefore indicated.
Nevertheless, it is important to note that effects of RACK on reversing age-related reductions in ischemic tolerance were independent of changes in PKC6 levels in aged. This observation is important since PKC6 activation upon reperfusion is known to increase apoptotic cell death and I/R injury (26, 33).
A proposed convergence point for many cardioprotective signals, including PKC , is inactivation of mitochondrial GSK-39 and associated apoptotic signaling. Specifically, inhibition of the mitochondrial transition pore by PKC is thought to involve phosphorylation and inhibition of mitochondrial GSK-3 (29) (48). Disruption of this model by aging is supported by our recent observations of I/R-dependent changes in mitochondrial pGSK-39 (23, 33 ). Here, we also observed three-fold greater levels of active mitochondrial GSK-39 only in aged during ischemia. Interestingly, inhibition of GSK-39 resulted in a similar degree of cardioprotection to that observed for acute PKC activation in aged hearts. In adult hearts, GSK-39 inhibition was less efficacious than ) RACK during the very early minutes of reperfusion, which may suggest a more robust effect of PKC activation on GSK-39 inhibition in aged vs adult hearts. Our observations of age-related reductions in mitochondrial PKC (and higher active GSK-39) during ischemia may predispose to elevated ROS and lowering of the MPT threshold, thereby increasing apoptotic cell death known to occur in aged (34, 40) . The agedependent increase in active mitochondrial GSK-39 demonstrated herein may also represent translocation of GSK-39 away from the nucleus, the impact of which may impinge upon transcription of cardioprotective genes. However, we can only speculate as to the mechanism of PKC -GSK-39 association since our studies did not directly address this issue.
Because signaling pathways associated with cardioprotection ultimately converge at the mitochondria (29, 38), we focused on the mitochondrial cellular compartment to identify additional mechanistic targets of PKC -mediated cardioprotection in the aged heart using a proteomic approach. The mitochondria play a critical role in the maintenance of cell survival, both due to maintenance of ATP production and reductions in apoptotic cell death (for review see (17, 20) ). Proteomic studies have revealed novel protein interactions involved in cardioprotection including PKC -ERK (16, 46, 48) and evidence has emerged regarding the role of signaling modules as a critical concept in the regulation of biological phenotypes (6, (46) (47) (48) .
A key protein identified in our proteomic analysis includes the F 1 -ATPase-9 subunit, which has recently been identified as part of a novel macromolecular supercomplex (3) 
Summary
Here, we present evidence for the first time that acute augmentation of mitochondrial PKC levels during ischemia through local peptide delivery is protective to the aged heart. Our data further suggest a novel interaction of the mitochondrial 
